DK Livkon: Contributing To Life

 Shirish Ahirekar,   Founder & Managing Director

Shirish Ahirekar

Founder & Managing Director

When it comes to administering drugs, the oral route has always been a popular one. How does the saying go? Over the lips, past the gums, look out stomach here it comes! Although it bears mentioning that all drugs that go over the lips are not destined for the stomach. Yes, there are medicines in pill form that are meant to be swallowed outright or chewed first and swallowed after but there are also drugs absorbed sublingually (underneath the tongue) and buccally (through the lining of the cheek). These methods of drug delivery have seen a surge in popularity over recent years, and for good reason. They provide a whole host of benefits to patients, drug administrators, and drug companies.

Relative to other drug delivery systems, oral thin films (OTFs) are a newer concept in medicine. Which drugs can and cannot be formulated for this method of delivery remains to be seen and largely depends on invention. The Oral delivery of a drug via thin film has the potential to improve the onset of action, lower the dosing, and enhance the efficacy and safety profile of the medicine. All tablets, soft gels liquid formulations primarily enter the blood stream via the gastrointestinal tract, which subject the drug to degradation from stomach acid, bile, digestive enzymes and other first-pass effects. As a result, such formulations often require higher doses and generally have a delayed onset of action. Buccal and sublingual thin-film drug delivery can avoid these issues and yield quicker onset of action at lower doses, thus reducing dose dependent side effects. Thin film is more durable and dissolves more quickly than other conventional dosage form, enabling improved dosing accuracy relative to liquid formulations. Each strip is manufactured to contain a precise amount of the drug.

D.K. Livkon is the leading manufacturer and exporter of oral thin films. D.K. Livkon is a pioneer in the novel drug delivery system, which unlike conventional drugs has the maximum absorption and efficacy.

A Legacy Unfolding
D K Group of Company has been producing APIs, Intermediates, Bulk Drugs, and Biotechnology for the medical industry for more than 40 years. As a member of the group, D.K. Livkon is also the biggest producers and exporters of oral disintegrating strips, often known as oral thin films(OTF) (ODS).

D.K. Livkon's production facility is FDA-approved and built in accordance with Class 100000 CGMP Guidelines. The firm has the capacity to produce more than 17 million strips every month, with a lot of room to grow. More than 70 oral thin film products in the pharmaceutical and nutraceutical sectors have so far been commercialised. In order to meet the global community's demands for health and wellness, D.K. Livkon's R& D team is continually developing new goods.

D.K Livkon strives to assess advanced medicines at affordable price. All the OTFs
products that D.K. Livkon offers are sugar free and flavoured. More important, the firm has innovated by bringing in only vegan products via natural sources.

Wide Spanning Product Portfolio
D.K. Livkon caters to the Therapeutical segments and manufactures drugs like Sildenafil,Tadalafil, Ondansetron,Simethicone and Methylcobalamine etc. all in the form of Oral Thin Films. D.K.Livkon also has developed assets for the Lifestyle & wellness segment under the brand name, Dr. Thins. Dr. Thins particularly covers an entire gamut of Lifestyle and Wellness ailments ranging from cosmetics to sleep disturbances to even hangover cure to immunity booster.

For instance, Dr. Thins Astaliv, is a plant-based, clinically researched product with natural strawberry flavor. This supplement is packed with natural astaxanthin, a powerful antioxidant that helps support your immune system, digestive system and optimizes your overall wellness. It even benefits muscle endurance, eye fatigue, and skin health. Be bold, be active, be you with the wellness benefits of Dr.Thins Astaliv oral strips. Likewise, Dr. Thins'Sleep mint Oral Strips is a non-habit forming solution that includes Melatonin that regulates your body clock and helps you fall asleep naturally. It is a plant-based, clinically researched ingredient.Dr. Thins helps restore balance with the thinnest, unsweetened anti-hangover strips that one can find ­ discreet and easy to use wherever a party takes.

Being a really advanced drug delivery system, OTFs have a plethora of advantages, and even more so with Dr. Thins products. Every product dissolves instantly on tongue with flavours, has faster & greater absorption than pills, jelly or capsule, does not require water to be consumed and thus no swallowing required, has better compliance, ensures more accurate dosing, and eliminates the first pass. It is especially beneficial for bedridden patients who tend to have difficulty swallowing.

As per MarketWatch's report, the global Oral Thin Films market size is estimated to be worth $3283 million in 2021 and is forecast to a readjusted size of $6624 million by 2028 with a CAGR of 10.4 percent during the forecast period 2022-2028

Founder's Vision
The Founder & Managing Director of D.K. Livkon Healthcare Pvt Ltd, Shirish Ahirekar has extensive years of experience in the Indian Pharma industry working with some of the pharma giants. Shirish envisions to bring some of the most crucial dosages into the thin film form, including anticancer medicines, antidiabeticetc."Given the lifestyle changes, heart problems and diabetes have become common in ages 30-40. With this thin film innovative technology, we have come up with a natural herbal dosage that helps producing insulin, that in turn, controls diabetes. I started this firm to ensure technology driven new dosage forms encompasses most critical lifestyle diseases", says Shirish.

Being a new, convenient, discreet, and elegant form, has received an impeccable response from consumers. Quite evidently, this novel drug delivery system offers most accurate dosage. One of the four key manufacturers of oral thin films in India, D.K. Livkon is poised to become the number one in the country and a premiere name globally.

As per MarketWatch's report, the global Oral Thin Films market size is estimated to be worth $3283 million in 2021 and is forecast to a readjusted size of USD 6624 million by 2028 with a CAGR of 10.4 percent during the forecast period 2022-2028. With these figures in mind, D.K. Livkon is prepared to cater to the market.

In the near future, the firm intends to access a greater market and manufacture OTFs for the Oncology(anticancer) segment hypertension, and wellness lifestyle products all in the form of the Novel Oral Thin Films dosage form.